Exelixis (NASDAQ:EXEL) has received a consensus rating of “Hold” from the sixteen research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $34.63.
A number of analysts have commented on EXEL shares. SunTrust Banks restated a “buy” rating and issued a $38.00 price target on shares of Exelixis in a research report on Thursday, December 21st. Cann restated a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research report on Tuesday, March 20th. Stifel Nicolaus upped their price target on Exelixis from $29.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Zacks Investment Research cut Exelixis from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. Finally, TheStreet cut Exelixis from a “b” rating to a “c+” rating in a research report on Thursday, March 15th.
EXEL traded down $0.21 during midday trading on Friday, reaching $20.64. The company had a trading volume of 907,466 shares, compared to its average volume of 3,129,178. The stock has a market cap of $6,098.00, a price-to-earnings ratio of 40.33 and a beta of 2.10. Exelixis has a 1 year low of $18.03 and a 1 year high of $32.50.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 EPS for the quarter, hitting analysts’ consensus estimates of $0.12. The business had revenue of $120.10 million during the quarter, compared to analysts’ expectations of $120.25 million. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The business’s quarterly revenue was up 54.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.12 earnings per share. equities research analysts forecast that Exelixis will post 0.54 EPS for the current year.
In related news, Director Vincent T. Marchesi sold 15,000 shares of the stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $24.73, for a total transaction of $370,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lance Willsey sold 30,000 shares of the stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $23.91, for a total value of $717,300.00. Following the sale, the director now owns 483,273 shares of the company’s stock, valued at approximately $11,555,057.43. The disclosure for this sale can be found here. Insiders have sold 105,029 shares of company stock valued at $2,703,787 in the last quarter. 5.10% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXEL. Sigma Planning Corp purchased a new position in Exelixis during the 4th quarter valued at approximately $208,000. American International Group Inc. purchased a new position in Exelixis during the 4th quarter valued at approximately $208,000. Klingenstein Fields & Co. LLC purchased a new position in Exelixis during the 4th quarter valued at approximately $213,000. Raymond James Financial Services Advisors Inc. purchased a new position in Exelixis during the 3rd quarter valued at approximately $236,000. Finally, Mackenzie Financial Corp grew its holdings in Exelixis by 24.1% during the 3rd quarter. Mackenzie Financial Corp now owns 10,116 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 1,963 shares in the last quarter. Institutional investors and hedge funds own 80.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Exelixis (EXEL) Receives Average Recommendation of “Hold” from Analysts” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://transcriptdaily.com/2018/04/13/exelixis-exel-receives-average-recommendation-of-hold-from-analysts.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.